Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

The Bsk mutation doesn't involve keratin gene recombination and its cause is unknown.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

The topical inhibitor CUR61414 was not effective in treating basal cell carcinoma in human trials.

The treatment was ineffective in humans.

Stat3 affects skin cancer development by altering keratinocyte stem cell behavior.

Changing the 6-position on benzopyran molecules affects insulin release, with some compounds showing strong inhibitory effects.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.

PEG and keratin scaffolds can effectively deliver protein drugs by controlling release based on pH levels.

Applying a specific inhibitor lightens skin and hair color.

Ginsenoside compound K shows promise for treating metabolic diseases like obesity and diabetes, but more research is needed on its safety and effectiveness.

Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

Keratinocyte Growth Factor-Hair Serum may help prevent hair loss during chemotherapy, but more research is needed.

JAK inhibition reduces autoimmune issues in Down syndrome.

GLI1 might protect against the start of skin cancer and is not linked to cancer severity.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Deucravacitinib effectively treats psoriasis and may help with other skin conditions.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.